0.2244

21.21% 0.0393

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $0.2244, with a volume of 1.78M. It is up +21.21% in the last 24 hours and down -51.83% over the past month. SANGAMO THERAPEUTICS INC

Previous Close:

$0.1851

Open:

$0.22

24h Volume:

1.78M

Relative Volume:

7.73

Market Cap:

$N/A

Revenue:

$39.55M

Net Income/Loss:

$-122.93M

P/E Ratio:

-0.5073

EPS:

-0.4423

Net Cash Flow:

$-97.31M

1W Performance:

+21.21%

1M Performance:

-51.83%

6M Performance:

-75.91%

1Y Performance:

-82.72%

1-Day Range:

$0.2141

$0.23

1-Week Range:

$0.2141

$0.23

52-Week Range:

$0.1172

$0.23

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (619)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

SGMO's Discussions on Twitter

Compare SGMO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMO Sangamo Therapeutics Inc	0.2234	0	39.55M	-122.93M	-97.31M	-0.4423
VRTX Vertex Pharmaceuticals Inc	427.48	107.89B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	621.43	63.21B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	809.32	49.89B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	290.71	38.20B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	155.63	32.17B	742.00K	-1.37B	-1.07B	-7.0731

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Barclays	Overweight → Equal Weight
Dec-13-24	Upgrade	Truist	Hold → Buy
Dec-10-24	Reiterated	H.C. Wainwright	Buy
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

May 28, 2026

Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Gregory D - Moomoo

May 28, 2026

May 27, 2026

Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan

May 27, 2026

Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan

May 27, 2026

Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan

May 27, 2026

Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan

May 27, 2026

May 22, 2026

Sangamo presents primate data for prion suppressor ST-506 - BioWorld News

May 22, 2026

May 17, 2026

Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN

May 17, 2026

May 16, 2026

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey

May 16, 2026

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks

May 16, 2026

May 15, 2026